4 / 32
ASCO 2016
3–7 JUNE 2016 • CHICAGO,
ILLINOIS, USA
The American Society
of Clinical Oncology
2016 Annual Meeting
saw the presentation of
key studies in glioma,
pancreatic cancer, lung
cancer, haematologic
cancers and much more.
PracticeUpdate Oncology
Associate Editor
Dr Isabel Cunningham
and Advisory Board
member Dr Jeffrey
Kirshner discuss their
top abstracts from
ASCO 2016.
Dr Isabel Cunningham
discusses key trials on
haematologic malignancies
presented at ASCO 2016
Isabel Cunningham MD is Adjunct Associate Research Scientist,
Division of Hematology Oncology, Columbia University College of
Physicians and Surgeons in New York.
Leukaemia, myelodysplastic syndromes,
and allotransplant
Optimizing chimeric antigen receptor (CAR) T cell
therapy for adult patients with relapsed or refractory
(r/r) acute lymphoblastic leukemia (ALL).
NV Frey, PA
Shaw, EO Hexner, et al
•
Researchers evaluated 27 adults with relapsed
or refractory acute lymphoblastic leukaemia
(ALL) who received CTL019 in one of four
dosing cohorts. Objective response rate (ORR)
was greatest at 83% with CTL019 dosed at 5 x
10
8
with fractionated dosing. ORRwas 33%with
5 x 10
7
and 50% with a single dosing of 5 x 10
8
.
A total of 9 of 12 patients receiving fractionated
CTL019 had grade 3 or higher cytokine release
syndrome, compared with 6 of 6 patients
receiving a single dose of 5 x 10
8
CTL019 and 6
of the 9 patients receiving 5 x 10
7
.
•
Researchers concluded that split dosing may
maintain efficacy while reducing the toxicity of
CTL019 in adults with relapsed or refractory
ALL.
Impact of disease burden on long-term outcome of
19-28z CAR modified T cells in adult patients with
relapsed B-ALL.
JH Park, I Riviere, X Wang, et al
•
In this phase I trial, 46 adults with relapsed
or refractory B-cell acute lymphoblastic
leukaemia (B-ALL) received lympho-depleting
chemotherapy followed by 19–28z chimeric
antigen receptor (CAR) T-cell infusion.
Complete response was observed in 91% of
patients with minimal disease burden (<5%
blasts) at baseline and 75% of patients with
morphologic disease burden (
≥
5% blasts).
While 44% patients with morphologic disease
burden experienced severe cytokine release
syndrome, it did not occur in any of the
patients with minimal disease burden. Grade
3 to 4 neurotoxicity also occurred more
frequently with morphologic versus minimal
disease burden (40% vs 14%, respectively),
and 6-month overall survival rate was 57% and
73%, respectively.
•
Researchers concluded that 19–28z CAR T-cell
infusion is effective for adults with relapsed
and refractory B-ALL. Minimal disease burden
is associated with better outcomes.
Inotuzumab ozogamicin (InO) for relapsed/refractory
(R/R) acute lymphoblastic leukemia (ALL) in the
phase III INO-VATE trial: Efficacy and safety by prior
therapy.
DJ DeAngelo, E Jabbour, M Stelljes, et al
•
In this ongoing phase 3 INO-VATE trial,
researchers evaluated 109 patients with
relapsed or refractory acute lymphoblastic
leukaemia (ALL) receiving inotuzumab
ozogamicin (InO) to determine the impact of
prior therapy on efficacy and safety. In patients
who received InO as salvage (S) 1, response
was numerically higher, remission duration
was longer, and rates of hepatobiliary adverse
events were significantly lower compared with
patients who received InO as S2. Prior stem
cell transplant (SCT) was associated with a
numerically lower rate of complete remission
with incomplete haematologic recovery and
a numerically higher rate of hepatobiliary
adverse events compared with no prior SCT.
•
Prior therapy and SCT increase the risk for
hepatotoxicity in patients taking InO; however,
patients with relapsed or refractory ALL
receiving InO as S1 or S2 therapy may gain
clinical benefit.
Impact of complete molecular response (CMR) on
survival in patients with Philadelphia chromosome-
positive (Ph+) acute lymphoblastic leukemia (ALL).
NJ
Short, E Jabbour, JE Cortes, et al
•
In a single-institution study, outcomes of 202
adult patients with Philadelphia chromosome-
positive (Ph+) acute lymphoblastic leukaemia
(ALL) were assessed to determine the
association of complete molecular response
(CMR) with survival.
AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2016 ANNUAL MEETING
4
PRACTICEUPDATE HAEMATOLOGY & ONCOLOGY